DEC 02, 2016 7:50 AM PST

Aspirin-Like Drug Prevents Progression of Head and Neck Cancer

WRITTEN BY: Kara Marker
People suffering from head and neck cancer can be treated through surgery, chemotherapy, and radiation, but a typical prognosis following treatment still isn’t very bright. Even when patients successfully receive these treatments, they only have a 50-50 chance of living more than five years.
Prostaglandin.
In search of a more effective and long-lasting treatment, scientists are jumping on the cancer immunotherapy bandwagon. This technique of boosting the immune system has worked for other types of cancer, and now researchers from the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center are seeking the same result for head and neck squamous cell carcinoma (HNSCC) patients. Although, senior author M. Rita Young, PhD, said that head and neck cancers are “notorious” for evading the immune system’s efforts to naturally eliminate tumor cells.

Young’s research prior to the present study showed that the composition of immune cells within premalignant lesions differs from that within progressed versions of HNSCC. During the transition from premalignant to malignant, Young found, the immune environment changed from inflammatory to immunosuppressive, preventing the immune cells from having any deleterious effect on the cancer cells. Young thought that a lipid mediator called prostaglandin might play a key role in the transitioning immune environments, and that idea led to her reaching the findings presented in her latest study.

Researchers used a mouse model of HNSCC to observe the impact on tumor progression while inhibiting prostaglandin. Treating premalignant lesions with a non-steroidal anti-inflammatory drug (NSAID), indomethacin, successfully inhibited prostaglandin. Then, the researchers saw a massive increase in immune cell presence, stimulation of the entire immune system, and a reduction in tumor burden on the body.

"If we can be more persistent and focused on finding premalignant lesions before they become malignant, simple therapies might be beneficial," explained postdoctoral fellow and co-author, Sara Johnson, PhD.

Specifically, inhibiting prostaglandin production with indomethacin led to an increase in Th1-associated cytokines - IL-2 and IFN-y - and Th2-associated cytokines, like IL-10. Cytokines like interleukins (ILs) and interferon (IFN) are chemical messengers used by the immune system to communicate under certain states of disease. In a given situation, the presence of certain cytokines indicate to scientists what response the immune system is attempting to produce.
M. Rita Young, Ph.D. Source: Medical University of South Carolina
Turning these findings into realistic action to prevent premalignant lesions from developing into cancer is Young’s next mission. First, she’ll have to confirm that inhibiting prostaglandin in humans yields the same results as in the mouse models of HNSCC. Then she’ll have to find the best candidate drug for inhibiting prostaglandin and boosting the immune system.

Young said, "Immunotherapy should be considered as a treatment strategy for premalignant lesions before they progress to cancer. We can detect them. Why not treat them?"

Young’s study was recently published in the journal Frontiers in Immunology.
 


Source: Medical University of South Carolina
Prostaglandin image: National Center for Biotechnology Information. PubChem Compound Database; CID=5280360
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 07, 2021
Microbiology
Positive Results From A Clinical Trial of an HIV Vaccine
FEB 07, 2021
Positive Results From A Clinical Trial of an HIV Vaccine
After years of effort, researchers are reporting that there were encouraging results from a phase 1 clinical trial which ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
FEB 23, 2021
Immunology
Immune Link Explains Why Personality Influences Mortality
FEB 23, 2021
Immune Link Explains Why Personality Influences Mortality
University of Limerick researchers have discovered direct links between the immune system, specific personality traits, ...
MAR 18, 2021
Immunology
COVID Cytokine Storm Chasers Look Inside the Lungs
MAR 18, 2021
COVID Cytokine Storm Chasers Look Inside the Lungs
Immunologists have revealed one of the underlying mechanisms behind COVID’s life-threatening cytokine storms. By s ...
MAY 24, 2021
Immunology
How Grief Can Affect the Immune System
MAY 24, 2021
How Grief Can Affect the Immune System
A new study by researchers at Rice University has shown that sleep loss often following the death of a spouse can have l ...
JUN 15, 2021
Clinical & Molecular DX
An Early Warning System for Type 1 Diabetes in Children
JUN 15, 2021
An Early Warning System for Type 1 Diabetes in Children
In type 1 diabetes, or T1D, the body’s own immune system mistakenly launches an aggressive attack on insulin-produ ...
Loading Comments...